In 2025, AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. So, revenue from Enhertu, which is a highly effective ...
AstraZeneca insists that its COVID-19 vaccine is strongly effective even after counting additional illnesses in its U.S. study, the latest in an extraordinary public dispute with American officials.
AstraZeneca (AZN) shares added ~2% in the premarket on Tuesday after the Anglo-Swedish drugmaker exceeded Street forecasts with its Q4 2025 financials, thanks mainly to its oncology portfolio. The U.K ...
AstraZeneca says that its COVID-19 vaccine is strongly effective even after counting additional illnesses in its U.S. study. The announcement late Wednesday was the latest in an extraordinary public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results